golpimec 0,5 mg kapsler, hårde
neuraxpharm sweden ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
gaxenim 0,5 mg kapsler, hårde
bausch health ireland limited - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
inzolfi 0,5 mg kapsler, hårde
sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
inzolfi 0,25 mg kapsler, hårde
sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,25 mg
bonaxon 0,5 mg kapsler, hårde
egis pharmaceuticals plc - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
efigalo 0,5 mg kapsler, hårde
krka d.d. novo mesto - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
fingod 0,5 mg kapsler, hårde
krka d.d. novo mesto - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
finrina 0,5 mg kapsler, hårde
genepharm s.a. - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
tysabri
biogen netherlands b.v. - natalizumab - multipel sclerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
aubagio
sanofi winthrop industrie - teriflunomide - multipel sclerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).